Open Access. Powered by Scholars. Published by Universities.®
Physical Sciences and Mathematics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
Articles 1 - 2 of 2
Full-Text Articles in Physical Sciences and Mathematics
Peppytides, Dave Zwicky
Peppytides, Dave Zwicky
2019 Symposium on Electronic Theses and Dissertations
Lightning talk for Symposium on Electronic Theses and Dissertations (ETD) at Purdue University on May 23, 2019.
Amino Alkynylisoquinoline And Alkynylnaphthyridine Compounds Potently Inhibit Acute Myeloid Leukemia Proliferation In Mice, N Naganna, Clement Opuku-Temeng, Eun Yong Choi, Elizabeth Larocque, Elizabeth T. Chang, Brandon A. Carter-Cooper, Modi Wang, Sandra E. Torregrossa-Allen, Bennett D. Elzey, Rena G. Lapidus, Herman Sintim
Amino Alkynylisoquinoline And Alkynylnaphthyridine Compounds Potently Inhibit Acute Myeloid Leukemia Proliferation In Mice, N Naganna, Clement Opuku-Temeng, Eun Yong Choi, Elizabeth Larocque, Elizabeth T. Chang, Brandon A. Carter-Cooper, Modi Wang, Sandra E. Torregrossa-Allen, Bennett D. Elzey, Rena G. Lapidus, Herman Sintim
Department of Chemistry Faculty Publications
B
ackground: Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to b10%. About 30% of AML patients harbor an activating mutation in the tyrosine kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD). In- hibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but pa- tients often relapse due to secondary mutations in the …